Kv7 voltage-gated potassium channel (Kv7) (Kv7)

Kv7 voltage-gated potassium channels, particularly the KCNQ2, KCNQ3, and KCNQ5 subunits, are essential regulators of neuronal excitability within the peripheral nervous system, including nociceptors. These channels generate the M-current, a low-threshold potassium current that stabilizes the resting membrane potential and acts as a "brake" against repetitive action potential firing [Brown DA, et al., 2009, British Journal of Pharmacology]. In nociceptors, the downregulation or inhibition of Kv7 channels leads to hyperexcitability and spontaneous firing, which are hallmarks of neuropathic and inflammatory pain [Wickenden AD, et al., 2004, Expert Opinion on Therapeutic Targets]. Therapeutic strategies involve the use of positive allosteric modulators, or "openers," which enhance the M-current to hyperpolarize the neuron and suppress pain signaling [Gunthorpe MJ, et al., 2012, British Journal of Pharmacology]. While early openers like retigabine proved the concept in clinical trials for epilepsy and pain, newer candidates such as XEN1101 and BHV-7000 are being developed to improve selectivity and reduce side effects like dizziness and urinary retention [Xenon Pharmaceuticals, 2023; Biohaven Ltd, 2024]. These channels represent a promising non-opioid target for the management of chronic pain conditions by directly addressing the underlying neuronal hyperexcitability [Nielsen AN, et al., 2022, Frontiers in Physiology].

Other names

KCNQ channelM-channelVoltage-gated potassium channel subfamily Q memberPotassium voltage-gated channel subfamily Q

Positive allosteric modulation of Kv7 channels, which increases the open-probability of the channel at resting potentials, leading to potassium efflux and membrane hyperpolarization [Gunthorpe MJ, et al., 2012, British Journal of Pharmacology].